NICE - Endorsed Technology Appraisals 2020/2021

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2020/2021

The following technology appraisals have been endorsed during 2020/21. Information on technology appraisals endorsed in previous years can be found on the homepage.

March 2021

TA681 - Baricitinib for treating moderate to severe atopic dermatitis

TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma

TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction

TA677 - Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma

TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis

TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

TA672 - Brolucizumab for treating wet age-related macular degeneration

TA671 - Mepolizumab for treating severe eosinophilic asthma Note this guidance updates and replaces NICE Technology Appraisal TA431, which was endorsed by the DoH in February 2017.

February 2021

TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

TA669 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies

‘Note this guidance has been updated and replaced by TA852 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments, which was endorsed by the DoH in January 2023.’

TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

January 2021

TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma

TA665 - Upadacitinib for treating severe rheumatoid arthritis

TA664 - Liraglutide for managing overweight and obesity

TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia

December 2020

TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

TA660 - Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

TA659 - Galcanezumab for preventing migraine

TA658 - Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

TA657 - Carfilzomib for previously treated multiple myeloma Note this guidance has been partially updated and replaced by TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma, which was endorsed by the DoH in May 2021

TA656 - Siponimod for treating secondary progressive multiple sclerosis

November 2020

TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy Note this guidance updates and replaces NICE Technology Appraisal TA483, which was endorsed by the DoH in January 2019.

TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

October 2020

TA651 - Naldemedine for treating opioid-induced constipation

TA650 - Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

TA649 - Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

September 2020

TA645 - Avelumab with axitinib for untreated advanced renal cell carcinoma

TA644 - Entrectinib for treating NTRK fusion-positive solid tumours